Biocytogen Boston Corporation Revenue and Competitors
Estimated Revenue & Valuation
- Biocytogen Boston Corporation's estimated annual revenue is currently $30.4M per year.
- Biocytogen Boston Corporation's estimated revenue per employee is $193,750
- Biocytogen Boston Corporation's total funding is $301M.
Employee Data
- Biocytogen Boston Corporation has 157 Employees.
- Biocytogen Boston Corporation grew their employee count by 20% last year.
Biocytogen Boston Corporation's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO Biocytogen Boston Corp | Reveal Email/Phone |
2 | VP | Reveal Email/Phone |
3 | CEO Biocytogen Boston Corporation | Reveal Email/Phone |
4 | CEO and CMO Eucure Biopharma | Reveal Email/Phone |
5 | VP, Global Head Business Development | Reveal Email/Phone |
6 | VP Operations | Reveal Email/Phone |
7 | Deputy General Manager and Chief Regulatory and Strategy Officer | Reveal Email/Phone |
8 | Senior Scientist II, Study Director and Flowcytometry Lead, Preclinical Pharmacology | Reveal Email/Phone |
9 | Director Product Development | Reveal Email/Phone |
10 | Senior Director, Preclinical Pharmacology | Reveal Email/Phone |
Biocytogen Boston Corporation Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Biocytogen Boston Corporation?
Biocytogen is a premier partner that provides one-stop solution for drug development, from concept to IND application. With cutting-edge technologies, state-of-art animal facility, and world-class platforms for efficient antibody drug development, Biocytogen offers animal model generation, antibody fully human RenMab mouse model, therapeutic antibody discovery and development, in vivo/in vitro preclinical studies, CMC/CDMO and regulatory affairs support. Biocytogen collaborates with more than 70% of top 50 pharmaceutical and biotech companies worldwide. Together, we discover innovative medicines for a better, healthier world. Welcome to reach out us at 781-587-3558 or send email to info@biocytogen.com.
keywords:N/A
$301M
Total Funding
157
Number of Employees
$30.4M
Revenue (est)
20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Biocytogen Boston Corporation News
This acquisition expanded Biocytogen's service platform in the Boston area. What Does the Report Cover? Future Market Insights offers a unique...
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology ... Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston,...
BOSTON, Feb. 25, 2021 /PRNewswire/ -- Biocytogen, a company dedicated to accelerating therapeutic antibody discovery, has announced the acquisition of a third Beacon Optofluidic system. The new instrument, developed by Berkeley Lights, will support the expansion of Biocytogen's antibody discov ...
Biocytogen, a Chinese clinical stage company, completed its series D1 funding raising USD 142m. The round was led by CMB International, with participation from investor partners PICC Capital, SDIC Ventures, China Life Equity, 3E Bioventures, Cowin Capital, and Baifu Capital. The company intend ...
In August, Beijing Biocytogen Biotechnology Co., Ltd. announced acquisition of Eucure Biopharma, which established Biocytogen as a clinical stage company. Now, Biocytogen is pleased to announce completion of series D1 Funding, successfully raising 142 million dollars (USD) meant to further secur ...
Other Companies in Wakefield
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $38M | 157 | 8% | N/A |
#2 | $15M | 158 | 0% | N/A |
#3 | $36.8M | 164 | 9% | N/A |
#4 | $51.4M | 173 | 38% | N/A |
#5 | $21.2M | 193 | N/A | N/A |